SynthesisWorld journal of surgical oncology2026
Ectopic breast cancer in vulva and other non-axillary sites: a systematic review.
Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Navigating lymphatic drainage uncertainty in abdominal ectopic breast cancer: a novel application of indocyanine green fluorescence-a case report and literature review.International cancer conference journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEctopic breast cancer (EBC) is a rare malignancy (0.3–0.6% of all breast cancers) that arises along the embryological milk line. While axillary EBC is better characterised and typically managed similarly to orthotopic breast cancer, the clinical features and management of non-axillary EBC remain poorly defined.
aimTo synthesise available data on the clinical presentation, histopathology, management, and outcomes of non-axillary EBC to refine treatment strategies.
methodsA systematic review of case reports and case series was conducted following PRISMA 2020 guidelines and registered with PROSPERO (CRD420251035771). PubMed, Ovid MEDLINE, Embase, Scopus, and Cochrane Library were searched up to April 2025. Study quality was assessed using the JBI checklist. Data were analysed descriptively using Microsoft Excel, focusing on clinical presentation, diagnosis, histopathology, treatment, and outcomes.
resultsSixty-one studies (63 patients) were included: 37 vulvar and 26 non-vulvar cases. Median age at diagnosis was 62. Lesions typically presented as painless nodules, with ulceration prompting attention. Invasive ductal adenocarcinoma was the most common histological subtype (39.7%), and oestrogen receptor positivity (82.5%) was frequent. Lymph node involvement was reported in 50.8% of cases. Organ metastases commonly involved bone, lung, and liver. Surgery was the main treatment, with adjuvant systemic therapy. Among cases with available follow-up (n = 50), recurrence and mortality rates were 18.0% (n = 9) and 16.0% (n = 8), respectively. Follow-up methods were poorly documented.
conclusionNon-axillary EBC shares clinical and pathological characteristics with orthotopic breast cancer. Multidisciplinary, site-adapted approach is recommended with applying breast cancer principles to systemic management. Increased clinical awareness and more consistent reporting are crucial to optimise future care and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.